
Glioblastoma (GBM) and high-grade glioma (HGG) are highly aggressive central nervous system malignancies with extremely high relapse rates, posing a severe threat to patient survival. Alfa Cytology is a global leader in cancer research. With our extensive experience and advanced platforms, our talented scientists provide one-stop solutions for GBM/HGG animal model development, efficacy evaluation, intracranial orthotopic model validation, post-resection relapse model studies, brain drug exposure testing, brain edema evaluation, neurological function observation, tumor immunology testing, pathology testing, molecular mechanism testing, and PK/PD, based on client candidate drugs, molecular mechanism, administration route, BBB penetration requirement, brain delivery approach, relapse research objective, and immune system dependence. We also provide zebrafish experimental services and cell-based experimental services, covering diverse research needs from in vitro to in vivo and from high-throughput screening to mechanism validation.
Introduction to Glioblastoma
GBM and HGG are central nervous system malignancies originating from glial cells and are the most common and most aggressive primary brain tumors. GBM/HGG is characterized by blood-brain barrier restriction, diffuse infiltration, high relapse rate, treatment resistance, and intracranial immunosuppression. Clinically, GBM is commonly treated with surgical resection combined with radiotherapy and temozolomide chemotherapy; MGMT promoter methylation status affects TMZ response. Relapsed and resistant patients rely more on novel targeted agents, ADCs, nanodelivery, local delivery, oncolytic virus, immunotherapy, and cell therapy. PI3K/AKT/mTOR, H3 K27M, EGFRvIII, IL13Rα2, B7-H3, and HER2 are important directions in current drug development. GBM/HGG is characterized by diffuse infiltration with unclear tumor boundaries, and postoperative relapse and minimal residual disease control are core issues in translational research. Blood-brain barrier penetration, intracranial drug distribution, brain edema, and neurological function impairment are key scenarios in drug evaluation. The GBM/HGG immune microenvironment is dominated by myeloid cells and microglia and is overall immunosuppressive, posing unique challenges for immunotherapy in this cancer type. Therefore, GBM/HGG animal studies need to be differentially designed based on molecular mechanism, brain delivery approach, BBB penetration requirement, relapse research objective, and immune system dependence, in order to better support candidate screening, efficacy evaluation, and clinical translation assessment.
Fig. 1 Glioblastoma landscape and path towards targeted therapies. (Landuzzi L, et al.; 2025)
Our Services
Alfa Cytology has established a comprehensive solution platform for glioblastoma / high-grade glioma animal experimental research, built around blood-brain barrier penetration, intracranial orthotopic microenvironment, local invasion, brain edema, neurological function impairment, postoperative relapse, minimal residual disease, radiotherapy combination, oncolytic virus, immunotherapy, and humanized cell therapy scenarios. Leveraging this integrated platform, Alfa Cytology provides end-to-end services covering the full GBM/HGG research workflow.
Preclinical Efficacy Studies
GBM/HGG drug development requires model selection based on molecular mechanism, administration route, BBB penetration requirement, brain delivery approach, relapse research objective, and immune system dependence. Alfa Cytology provides integrated animal study solutions, from cell line selection to model validation, for small molecule targeted agents, ADCs, nanodelivery, local delivery, radiotherapy combination, oncolytic virus, immune checkpoint inhibitors, STING agonists, cytokines, TCEs, CAR-T/NK, and humanized cell therapy programs.
Candidate Screening
Early screening typically requires rapid assessment of whether a candidate demonstrates in vivo antitumor signals. Alfa Cytology conducts TGI, RTV, PK/PD, MGMT, γH2AX, and target evaluations using subcutaneous CDX models, providing data to support dose selection, dosing frequency, and candidate prioritization.
Clinical Relevance Studies
When programs advance to BBB penetration, intracranial orthotopic microenvironment, local invasion, brain edema, neurological function impairment, postoperative relapse, minimal residual disease, or radiotherapy combination stages, Alfa Cytology can further configure human intracranial orthotopic models, GSC stem-like intracranial orthotopic models, post-resection relapse models, post-radiotherapy residual and rechallenge models, GL261/CT-2A syngeneic immunocompetent models, or humanized immune models to help clients generate evidence more aligned with clinical scenarios.
GBM and HGG Mechanism Research
For BM/HGG studies, experimental design typically needs to address blood-brain barrier, intracranial microenvironment, diffuse infiltration, brain edema, relapse mechanisms, and immunosuppression simultaneously. Alfa Cytology provides model development, dosing intervention, pathology testing, immunology testing, protein testing, and RNA testing services, covering MGMT, EGFRvIII, IL13Rα2, B7-H3, HER2, H3 K27M, PI3K/AKT/mTOR, SOX2, OLIG2, CD133, Nestin, brain edema, relapse, and MRD clearance.
In Vitro and In Vivo Layered Validation
Animal studies can address whether a candidate inhibits intracranial tumor growth, local invasion, brain edema, neurological function impairment, or postoperative relapse; zebrafish platforms provide high-throughput in vivo screening covering tumor proliferation, intracranial colonization, local invasion, angiogenesis, immune co-culture, and drug toxicity; cell-based experiments validate proliferation, apoptosis, migration and invasion, MGMT, EGFRvIII, PI3K/AKT/mTOR pathway, stemness maintenance, drug internalization, and immune killing.
Molecular Mechanism Studies
Depending on program needs, we offer IHC, IF, flow cytometry, ELISA, Western blot, qPCR, RNA-seq, GFAP, Nestin, OLIG2, SOX2, CD133, Ki67, CD31, Iba1, CD8, FoxP3, γH2AX, MGMT, pAKT, pERK, cytokines, flow cytometry immune profiling, and spatial histology testing.
For clients with only a candidate drug, target direction, or preliminary mechanistic hypothesis, Alfa Cytology assists in structuring cell line selection, model pathways, group design, dosing regimens, detection endpoints, terminal sample collection, and data presentation,translating R&D questions into executable animal study protocols. Our capabilities support a broad spectrum of therapeutic modalities, including but not limited to:
Supported R&D Programs
| R&D Project |
Cell Lines |
Host System |
Preferred Model |
Key Endpoints |
| Early efficacy screening |
U87MG, U251, LN229, T98G |
BALB/c nude, NOD-SCID, NSG |
Subcutaneous CDX |
TGI, RTV, terminal tumor weight, Ki67, apoptosis, γH2AX, PK/PD. |
| BBB penetration and brain exposure |
U87MG-luc, U251-luc, LN229-luc, T98G-luc, GSC-luc |
Nude, NOD-SCID, NSG/NOG |
Human orthotopic intracranial model |
MRI/BLI, survival, brain drug concentration, tumor core/margin exposure, normal brain exposure. |
| Stem-like / high-invasive GBM |
GSC11, GSC23 and other GSC lines |
NSG/NOG |
GSC orthotopic model |
Diffuse infiltration, SOX2, OLIG2, CD133, Nestin, microvascular proliferation, necrosis, survival. |
| TMZ sensitivity and resistance |
T98G, LN229, U251 subcutaneous or intracranial, with resistant lines if needed |
T98G, LN229, U251, MGMT-high or resistant derivatives |
TMZ response, MGMT, γH2AX, apoptosis, regrowth rate, survival |
Requires MGMT status and DNA damage markers; tumor volume alone is insufficient. |
| Radiotherapy combination / radiosensitization |
U251-luc, LN229-luc, T98G-luc, GSC-luc, GL261-luc, CT-2A-luc |
NOD-SCID, NSG, NOG, C57BL/6 |
Orthotopic model, with post-radiation residual and rechallenge |
MRI/BLI, survival, γH2AX, apoptosis, brain edema, residual tumor, regrowth rate. |
| Post-surgery adjuvant / resection recurrence |
GL261-luc, CT-2A-luc, U87MG-luc, GSC-luc |
C57BL/6, NSG, NOG |
Orthotopic model + craniotomy debulking/partial resection |
Recurrence time, PFS, OS, recurrent tumor burden, infiltrative margin, local immunity. |
| Local delivery / resection cavity implant |
U87MG-luc, GSC-luc, GL261-luc, CT-2A-luc |
Nude, NSG, C57BL/6 |
Orthotopic or resection-recurrence model |
Brain distribution, cavity exposure, local toxicity, recurrence delay, survival, brain pathology. |
| Oncolytic virus / STING / local immune activation |
GL261-luc, CT-2A-luc |
C57BL/6 |
Syngeneic orthotopic model, preferred |
Survival, BLI, T cell infiltration, myeloid cells, microglia, cytokines, local inflammation. |
| Immune checkpoint and radio-immunotherapy |
GL261, CT-2A |
C57BL/6 |
Syngeneic subcutaneous screening + syngeneic orthotopic validation |
CD8/Treg, Iba1, myeloid suppression, PD-L1, IFN-γ, Granzyme B, survival. |
| TCE / CAR-T / CAR-NK / human immune-dependent |
U87MG, GSC11, GSC23 or target-positive models |
huPBMC or huHSC/BLT |
Humanized immune model |
hCD45, hCD3, hCD8, CAR/TCE activation, cytokines, brain toxicity, xGvHD/CRS risk. |
| H3 K27M / diffuse midline glioma |
H3 K27M-related cells or PDX/GSC models |
NSG, NOG |
Molecularly matched model, orthotopic if needed |
H3K27me3, ONC201/DRD2/ClpP-related markers, survival, brain burden. |
| Brain edema and anti-angiogenesis |
U87MG-luc, GSC-luc, GL261-luc, CT-2A-luc |
Nude, NSG, C57BL/6 |
Orthotopic model |
MRI edema, CD31, VEGF, vascular permeability, brain water content, neurological score. |
Comprehensive Test and Data Analysis Platform
For Ewing Sarcoma programs focused on EWSR1::FLI1 fusion-driven disease, bone orthotopic microenvironment, bone destruction, and lung metastasis evaluation, we configure TGI, RTV, terminal tumor weight, BLI/IVIS, orthotopic tumor burden, X-ray, micro-CT, bone destruction score, lung nodule count, lung weight, survival, CD99, EWSR1::FLI1 fusion transcript, Ki67, cleaved caspase-3, γH2AX, PARP, cell cycle markers, angiogenesis markers, hCD45 reconstitution rate, hCD3, hCD8, hNK, cytokines, tumor tissue drug concentration, and bone tissue exposure, forming an integrated data chain linking fusion gene background, bone microenvironment, lung metastasis, and immune microenvironment.
Multimodal In Vivo Imaging
- IVIS Spectrum photon bioluminescence quantification for bone orthotopic tumors, lung metastasis, and postoperative relapse tracking
- 7.0T small-animal high-field MRI and ultrasound for intraosseous lesion and cortical bone destruction scanning
- micro-CT 3D reconstruction for osteolysis, bone destruction score, and bone mineral density assessment
Pathology and IHC/IF Staining
- CD99 / EWSR1::FLI1 fusion transcript / γH2AX / PARP pathway and target assessment
- Ki67 / Cleaved-Caspase 3 proliferation and apoptosis index
- mIF multiplex immunofluorescence for in situ target and Ewing Sarcoma TME quantification
TME Microenvironment and Immune Profiling
- Bone/bone marrow immune cell multicolor flow cytometry
- CD8/Treg, MDSC, and macrophage subset analysis
- Cytokine storm (IFN-γ / IL-6) CBA suspension array
Access Our Glioblastoma Model Library
Glioblastoma Cell Line Panel
Alfa Cytology's GBM/HGG cell line panel covers blood-brain barrier penetration, intracranial orthotopic microenvironment, diffuse infiltration, radiotherapy combination, and immuno-oncology, enabling cell line selection and matching based on molecular mechanism, brain delivery route, recurrence research objective, and immune system requirements.
Standard Human Glioma Cell Lines
- U87MG: stable tumor formation and good reproducibility; both subcutaneous and intracranial orthotopic models are relatively easy to establish, suitable for early efficacy evaluation, dose exploration, and PK/PD research; U87MG-luc can be used for intracranial orthotopic dynamic monitoring.
- U251: commonly used for DNA damage, radiotherapy combination, migration and invasion, and temozolomide-related research.
- LN229: suitable for p53-related, DNA damage repair, combination therapy, and temozolomide response research.
- T98G: commonly used for MGMT expression, temozolomide resistance, and radiotherapy tolerance research.
GSC Stem-Like and High-Invasion Cell Lines
- GSC11: with glioma stem cell-like characteristics, suitable for studying intracranial infiltration, resistance, relapse, stemness maintenance, and brain microenvironment.
- GSC23: suitable for clinical translation, infiltration margin, post-radiotherapy residual, and relapse research.
- PDX or GSC models better reflect tumor heterogeneity and clinical-like phenotypes, but have longer cycles and more complex standardization; suitable for key candidate validation.
Syngeneic Immunocompetent-Related Cell Lines
- GL261: one of the most widely used syngeneic glioma models in C57BL/6 background, suitable for immune checkpoint, radiotherapy combination, oncolytic virus, STING, cytokines, TME remodeling, and single-cell/spatial immune analysis.
- CT-2A: typically exhibits higher invasiveness and immunosuppressive characteristics, suitable for malignant phenotype, myeloid suppression, immune resistance, and local immune microenvironment research.
- Immunotherapy programs should not remain in syngeneic subcutaneous models for extended periods. If the program targets the intracranial immune microenvironment, microglia/macrophages, blood-brain barrier, and survival benefit, escalation to syngeneic intracranial orthotopic models should occur as early as possible.
Molecular Mechanism and Target Selection-Related Cell Lines
- Temozolomide programs should clarify MGMT status and combine γH2AX, cell cycle, apoptosis, and regrowth rate to judge efficacy; T98G is more suitable for MGMT-high expression or TMZ resistance research.
- PI3K/AKT/mTOR programs can use standard CDX for screening, then escalate to intracranial orthotopic models to validate brain exposure and survival benefit.
- H3 K27M or diffuse midline glioma programs should select molecular background-matched models and detect H3K27me3, DRD2/ClpP-related markers, and intracranial survival endpoints.
- EGFRvIII, IL13Rα2, HER2, B7-H3, EphA2 and other immune target programs should first confirm target expression, then select CDX, humanized models, or in vitro killing linkage based on whether human immune cells are required.
Glioblastoma Animal Model Panel
Alfa Cytology provides end-to-end GBM/HGG animal model development services, spanning model design, cell line selection, model construction, dosing intervention, efficacy evaluation, pathology, immunology, molecular mechanism testing, and PK/PD analysis. The models below represent our core capabilities across blood-brain barrier penetration, intracranial orthotopic microenvironment, local invasion, brain edema, neurological function impairment, postoperative relapse, minimal residual disease, radiotherapy combination, oncolytic virus, immunotherapy, and humanized cell therapy research. Each model can be customized to match your program's molecular mechanism, administration route, BBB penetration requirement, brain delivery approach, relapse research objective, and immune system dependence, from early screening to clinical relevance validation.
Subcutaneous Xenograft Model (CDX)
Subcutaneous CDX models typically involve inoculating human GBM/HGG cells subcutaneously into immunodeficient mice, followed by randomization and dosing once tumors reach a predetermined volume. Commonly used hosts include BALB/c nude, NOD-SCID, NSG, or NOG mice. Commonly used cell lines include U87MG, U251, LN229, and T98G, with conventional inoculation amounts of 1×10^6–5×10^6 cells.
Model characteristics
U87MG, U251, LN229, and T98G are suitable for early efficacy, dose exploration, PK/PD, temozolomide response, DDR, and mechanism screening. GSC11 and GSC23 models can also be used for early candidate screening, but have higher value in intracranial orthotopic settings. This model has high standardization, suitable for early screening and candidate ranking, but cannot address BBB penetration, intracranial distribution, brain edema, and survival benefit.
Modeling and dosing timelines
Inoculation typically reaches enrollment volume within 1–4 weeks, with randomization commonly performed at tumor volumes of approximately 80–150 mm3. The conventional treatment period is 2–4 weeks. For resistance, withdrawal rechallenge, sustained-release formulations, or long-term combination therapy, this can be extended to 4–8 weeks. Small molecules can be dosed daily or every other day; temozolomide can use short-cycle consecutive dosing; ADCs, antibodies, and long-acting formulations can be dosed weekly or at intervals based on half-life.
Detection endpoints
- Basic efficacy layer: TGI, RTV, terminal tumor weight, body weight, general condition, progression-free time, and survival
- Mechanism layer: Ki67, cleaved caspase-3, TUNEL, γH2AX, MGMT, pAKT, pERK, p-mTOR, and target pathway markers
- PK/PD layer: Plasma drug concentration, tumor tissue concentration, target inhibition, pathway inhibition, and exposure-efficacy relationship
- Safety layer: Body weight, complete blood count, liver and kidney function, major organ pathology, and dosing tolerance
Recommended positive controls
Temozolomide at 25–50 mg/kg oral or IP, daily for 5 consecutive days or cyclically. Bevacizumab as a mechanism reference for angiogenesis, edema, or imaging response. Paxalisib as a PI3K/AKT/mTOR direction development reference.
Standard Cell Line Intracranial Orthotopic Model
Standard cell line intracranial orthotopic models typically use stereotactic injection to inoculate U87MG-luc, U251-luc, LN229-luc, or T98G-luc into the mouse brain, commonly targeting the striatum or specific brain regions. Fixed coordinate protocols, injection volume, cell number, injection speed, and needle retention time are typically required to reduce reflux and brain surface dissemination risk.
Model characteristics
U87MG-luc is suitable for stable tumor formation and early intracranial efficacy validation; U251-luc is suitable for DNA damage, radiotherapy, and migration research; LN229-luc is suitable for p53/DDR-related research; T98G-luc is suitable for MGMT/TMZ resistance direction. This model is suitable for BBB penetration, intracranial distribution, brain edema, neurological function, survival benefit, and intracranial drug exposure research, with high technical requirements, significant inter-batch variability, and sensitive surgical windows.
Modeling and dosing timelines
Luc-labeled models typically undergo first in vivo imaging confirmation 3–7 days after modeling; MRI monitoring models can establish baseline at days 7–14. Early intervention is suitable for BBB penetration and intracranial drug delivery research; post-imaging intervention is closer to post-diagnosis treatment; pre-neurological-symptom intervention is suitable for survival benefit research. The conventional treatment period is 2–6 weeks. Intracranial models place more emphasis on survival, imaging progression delay, and neurological function maintenance.
Detection endpoints
- Imaging and survival layer: MRI, BLI/IVIS, tumor burden, survival, progression-free time, and neurobehavioral scoring
- Brain edema and BBB layer: Brain edema extent, BBB permeability, brain water content, vessel density, CD31, and VEGF
- Invasion and pathology layer: HE, GFAP, Nestin, Ki67, CD31, Iba1, microvascular proliferation, necrosis, and invasive margin
- Intracranial exposure layer: Plasma drug concentration, tumor core drug concentration, invasive margin concentration, normal brain tissue concentration, brain/plasma ratio, and exposure-efficacy correlation
Recommended positive controls
Temozolomide as a standard reference for intracranial orthotopic models. Radiotherapy combined with temozolomide can simulate the standard treatment pathway. Bevacizumab as a mechanism reference for angiogenesis, edema, or imaging response. Paxalisib as a PI3K/AKT/mTOR direction development reference; dordaviprone / ONC201 is more oriented toward H3 K27M / diffuse midline glioma-related development reference.
GSC Stem-Like Intracranial Orthotopic Model
GSC stem-like intracranial orthotopic models typically use GSC11-luc, GSC23-luc, and other patient-derived glioma stem cell-like models inoculated into the mouse brain via stereotactic injection. This model is more suitable for studying invasive margins, stemness maintenance, microvascular proliferation, necrosis-like areas, post-radiotherapy residual disease, and relapse.
Model characteristics
GSC models more readily form diffuse invasive margins, heterogeneity, and relapse-related phenotypes in the intracranial setting than conventional adherent cells. If the program focuses on clinical translation, invasion, resistance, relapse, and post-radiotherapy residual disease, at least one GSC model should be introduced in parallel with standard cell lines. This model has longer cycles and greater inter-batch variability, but is closer to clinical invasion and relapse.
Modeling and dosing timelines
GSC models typically require confirmation of sphere status and stemness markers before intracranial inoculation. Luc-labeled models can be monitored by BLI/IVIS. The conventional treatment period is 3–6 weeks. If studying postoperative relapse, post-radiotherapy residual disease, or long-term maintenance, the observation period can be extended.
Detection endpoints
- Invasion and pathology layer: Diffuse infiltration, invasive margin, HE, GFAP, Nestin, microvascular proliferation, and necrosis-like areas
- Stemness layer: SOX2, OLIG2, CD133, Nestin, and tumor stemness
- Imaging and survival layer: MRI, BLI/IVIS, tumor burden, survival, progression-free time, and neurobehavioral scoring
- Relapse layer: Post-treatment residual disease, relapse-related markers, and invasive margin
Recommended positive controls
Temozolomide as a basic reference. Radiotherapy combined with temozolomide can simulate the standard treatment pathway. Dordaviprone / ONC201 is more oriented toward H3 K27M / diffuse midline glioma-related development reference. Paxalisib as a PI3K/AKT/mTOR direction development reference.
Post-Resection Relapse Model
Post-resection relapse models are typically based on GL261-luc, CT-2A-luc, U87MG-luc, or GSC-luc intracranial orthotopic models. Tumor resection window is first confirmed by BLI or MRI, followed by craniotomy debulking or partial resection, then postoperative treatment and relapse tracking. Complete resection is typically not pursued in mouse models; instead, minimal residual disease is retained to simulate clinical postoperative residual status.
Model characteristics
Suitable for postoperative adjuvant therapy, resection cavity local delivery, local implants, post-radiotherapy maintenance, and MRD clearance research. This model is closest to the clinical relapse pathway of GBM/HGG, but has complex procedures, higher mortality and variability, and high requirements for surgical consistency, imaging monitoring, and long-term follow-up.
Modeling and dosing timelines
Common regimens include initiating treatment 24–72 hours postoperatively, postoperative radiotherapy combined with drugs, postoperative local implant release, or treatment after relapse imaging signals appear. The total cycle is typically longer than simple intracranial orthotopic models.
Detection endpoints
Time to relapse, PFS, OS, relapsed lesion volume, relapse margin invasion, local immune environment, resection cavity drug distribution, reflux, local toxicity, neurological function, and survival.
Recommended positive controls
Temozolomide as a basic postoperative adjuvant therapy reference. If simulating the standard pathway, local radiotherapy can be combined. Rhenium obisbemeda / 186RNL and other local radionuclide delivery strategies can serve as local therapy development references.
Post-Radiotherapy Residual and Rechallenge Model
Post-radiotherapy residual and rechallenge models involve administering local radiotherapy after intracranial orthotopic models form stable imaging, then observing signal decline and regrowth.
Model characteristics
This model is suitable for radiosensitizers, post-radiotherapy maintenance therapy, and relapse inhibition drug research. Treatment can be initiated 24–72 hours after radiotherapy, maintenance therapy can be initiated within 5–7 days after radiotherapy, or rechallenge can occur after signal regrowth. Radiotherapy can alter BBB and blood-tumor barrier permeability; combination delivery programs should validate treatment sequence and drug distribution changes in orthotopic models.
Detection endpoints
Post-irradiation tumor signal decline, regrowth rate, survival, γH2AX, apoptosis, brain edema, vascular permeability, pre- and post-irradiation brain tissue drug concentration, DCE-MRI, relapsed lesion invasion, and local immune changes.
Recommended positive controls
Radiotherapy combined with TMZ as a basic reference; DDR or PI3K/AKT/mTOR direction drugs can set combination groups based on mechanism.
Syngeneic Subcutaneous Model
GL261 or CT-2A cells can be inoculated subcutaneously in C57BL/6 mice to establish an early immune efficacy platform in an intact immune system background. Treatment is typically initiated when tumors reach approximately 50–80 mm3, with a treatment period of typically 10–21 days.
Model characteristics
This model is suitable for immune checkpoint, STING, cytokines, and combination therapy early screening. It can address basic immune activity, but lacks BBB, intracranial microenvironment, and microglia participation, and should not be used as the final decision model for immunotherapy programs.
Detection endpoints
Tumor volume, TGI, survival, body weight, flow cytometry immune profiling, cytokines, CD8/Treg, myeloid cells, and IHC/IF.
Recommended positive controls
anti-PD-1, anti-PD-L1, or anti-CTLA-4 can be administered IP at 100–200 μg/mouse, twice weekly or once every 3 days, for 2–3 consecutive weeks.
Syngeneic Intracranial Orthotopic Model
GL261-luc and CT-2A-luc can establish intracranial orthotopic models in C57BL/6 mice, typically via stereotactic injection. Cell numbers are typically lower than human models to avoid overly rapid growth leading to short treatment windows.
Model characteristics
This model is suitable for PD-1/PD-L1, CTLA-4, STING, oncolytic virus, cytokines, CAR-T/NK, radiotherapy combination, TME remodeling, and intracranial immune mechanism research. This model combines the intracranial organ environment and intact immune system, making it a high-priority platform for immunotherapy programs. Its limitation is that murine tumors differ from human GBM in targets and heterogeneity.
Detection endpoints
BLI/MRI, survival, CD8/Treg, MDSC, macrophages/microglia, Iba1, CD68, PD-L1, IFN-γ, Granzyme B, TCR repertoire, single-cell sequencing, and spatial immune analysis.
Recommended positive controls
anti-PD-1, anti-PD-L1, or anti-CTLA-4 can be administered IP at 100–200 μg/mouse, twice weekly or once every 3 days, for 2–3 consecutive weeks. STING, oncolytic virus, and radiotherapy combination require separate design based on mechanism and local safety.
The huPBMC model establishes a short-term human immune effector environment by infusing human peripheral blood mononuclear cells into immunodeficient mice, combined with U87MG, GSC11, GSC23, or other target-positive human GBM models, for short-cycle human immune effector validation.
Model characteristics
This model is suitable for TCE, CAR-T/NK, human cytokines, human immune checkpoints, early immune activation, and cytokine release risk assessment. This model has high cost, significant donor variability, limited experimental windows, and carries xGvHD or cytokine release risk; it is not recommended as an early screening platform.
Detection endpoints
hCD45, hCD3, hCD4, hCD8, hNK, T cell activation, tumor infiltration, IFN-γ, TNF-α, IL-6, Granzyme B, intracranial toxicity, body weight, CRS, and xGvHD risk markers.
Recommended positive controls
anti-human PD-1, anti-human PD-L1, or anti-human CTLA-4 can serve as mechanism references. EGFRvIII, IL13Rα2, B7-H3, HER2, or EphA2 direction TCE/CAR-T programs should include target-positive, low/negative, effector cell, and empty vector/irrelevant TCE controls. Cell therapy doses are often designed on the order of 10^6–10^7 cells/mouse.
huHSC / BLT + Human GBM Model
huHSC or BLT humanized models can establish a longer-term human immune reconstitution background, suitable for complex immune mechanisms, human immune cell differentiation, T cell exhaustion, and combination therapy research.
Model characteristics
This model is suitable for CAR-T/NK long-term persistence, TCE, human immune checkpoints, myeloid cell involvement, immune resistance, and GSC model combination validation. This model has high cost, significant donor variability, and carries xGvHD or cytokine release risk; it is not recommended as an early screening platform.
Detection endpoints
Human immune reconstitution ratio, T/B/NK/myeloid cell spectrum, tumor infiltration, cytokines, human immune checkpoint expression, intracranial tumor burden, survival, and major organ pathology.
Recommended positive controls
anti-human PD-1, anti-human PD-L1, or anti-human CTLA-4 can serve as mechanism references. CAR-T/TCE programs should include target-positive, low/negative, and irrelevant TCE controls. Cell therapy doses are often designed on the order of cells/mouse.
How to Select the Right Model for Your Program?
By Development Stage
By Drug Type
By Research Objective
By Route of Administration
By Development Pathway
- Early candidate screening: Prioritize subcutaneous CDX. U87MG, U251, LN229, and T98G can serve as standardized early screening platforms.
- Intracranial scenario validation: For BBB penetration, intracranial distribution, brain edema, neurological function, and survival, escalate to intracranial orthotopic models.
- Invasion and relapse validation: For invasive margin, residual disease, post-radiotherapy regrowth, or postoperative adjuvant therapy, use GSC intracranial orthotopic, post-resection relapse, or post-radiotherapy residual rechallenge models.
- Immune confirmation stage: For immune checkpoint, STING, oncolytic virus, cytokines, CAR-T/NK, or radiotherapy-immune combination, prioritize GL261 or CT-2A syngeneic intracranial orthotopic models. Human immune-dependent programs escalate to humanized models.
- Small molecules and BBB-penetrant agents: Validate basic efficacy in subcutaneous CDX first, then evaluate intracranial exposure, survival, and intracranial pathway inhibition in orthotopic models.
- TMZ sensitization and DDR programs: Select U251, LN229, T98G, or GSC models; evaluate γH2AX, MGMT, RAD51, cell cycle, and apoptosis.
- ADCs and nanodelivery systems: Focus on BBB, blood-tumor barrier, intracranial distribution, and tumor margin exposure. Subcutaneous CDX is only for early activity assessment.
- Local delivery and implants: Resection cavity implants, local sustained release, intratumoral injection, periventricular delivery, and local radionuclide formulations prioritize intracranial orthotopic or post-resection relapse models.
- Immunotherapy and oncolytic virus: PD-1/PD-L1, CTLA-4, STING, oncolytic virus, cytokines, and radiotherapy combination prioritize GL261/CT-2A syngeneic orthotopic models.
- TCE and CAR-T/NK: Confirm target expression, then combine huPBMC or huHSC humanized models, in vitro killing, and intracranial toxicity assessment.
- Rapid tumor shrinkage and PK/PD: Subcutaneous CDX; endpoints include TGI, RTV, terminal tumor weight, and pathway inhibition.
- Intracranial exposure and survival benefit: Intracranial orthotopic models; endpoints include MRI/BLI, survival, brain tissue drug concentration, tumor margin exposure, and neurobehavior.
- Diffuse infiltration and stemness: GSC intracranial orthotopic models; endpoints include invasive margin, SOX2, OLIG2, CD133, Nestin, microvascular proliferation, and necrosis-like areas.
- Postoperative relapse and MRD clearance: Post-resection relapse models; endpoints include time to relapse, PFS, OS, relapsed lesion burden, and local immunity.
- Post-radiotherapy residual and rechallenge: Post-radiotherapy residual models; endpoints include post-irradiation signal decline, regrowth rate, γH2AX, apoptosis, and survival.
- Immune microenvironment remodeling: Syngeneic intracranial orthotopic models; endpoints include CD8/Treg, myeloid cell profile, Iba1, CD68, PD-L1, and cytokines.
- Systemic administration: Oral, intraperitoneal, intravenous, and subcutaneous dosing are suitable for subcutaneous CDX, intracranial orthotopic, and immune models. Systemic dosing programs require parallel measurement of plasma concentration and brain tissue exposure.
- Intratumoral or intracranial local administration: Intratumoral, peritumoral, periventricular, local sustained-release, and resection cavity implants are suitable for intracranial orthotopic or relapse models.
- Radiotherapy combination: Define irradiation dose, fractionation, dosing sequence, and sampling window. For standard-of-care simulation, radiotherapy combined with TMZ can serve as a basic reference.
- Cell therapy dosing: CAR-T/NK, TCE, and immune cell therapy can be dosed intravenously, intracranially, intraventricularly, or intratumorally; monitor cytokines, intracranial inflammation, and neurotoxicity.
- Small molecules / ADCs / nanodelivery: Subcutaneous CDX early screening → intracranial orthotopic validation of brain exposure → post-resection relapse model to validate relapse control.
- Immunotherapy: GL261/CT-2A syngeneic subcutaneous early screening → syngeneic intracranial orthotopic validation → humanized immune model for human immune-dependent mechanism confirmation.
- Radiotherapy and local therapy: Intracranial orthotopic model → local radiotherapy or local dosing → post-radiotherapy residual / post-resection relapse model for deeper evaluation.
- Relapse programs: Intracranial orthotopic modeling → imaging confirmation → craniotomy debulking or post-radiotherapy residual → postoperative or post-radiotherapy maintenance intervention → long-term follow-up.
Why Alfa Cytology?
Blood-Brain Barrier & Infiltrative Microenvironment Modeling
Glioblastoma requires overcoming the blood-brain barrier (BBB) and navigating diffuse, invasive margins. Alfa Cytology designs tailored evaluation pathways based on core genetic profiles (IDH status, MGMT promoter methylation, EGFR amplification) and infiltrative behavior, avoiding superficial subcutaneous-only misinterpretation.
Stratified Cell Line & Orthotopic Directory
Model selection determines intracranial engraftment and survival readouts. Alfa Cytology helps clients match optimal systems—such as U87MG, U251, LN229, T98G, and GSC (glioma stem cell) models—based on intracranial growth kinetics, stemness features, and therapeutic resistance.
Intracranial Orthotopic & Post-Surgical Recurrence Models
Subcutaneous models cannot address BBB penetration, intra-tumoral drug distribution, or post-surgical recurrence. Alfa Cytology helps clients generate high-fidelity translational evidence through stereotactic intracranial orthotopic implantation and resection cavity recurrence models.
Target Validation & Integrated Neuro-Oncology PK/PD
Programs targeting immune checkpoints, CAR-T/NK cell therapies, or small molecules require deep brain penetration analysis. Alfa Cytology configures bioluminescence imaging (BLI), neurological scoring, brain edema assessment, and integrated intracranial PK/PD workflows to track core and invasive edge drug concentrations.
Alfa Cytology is a global leader in GBM/HGG translational research, delivering integrated animal model solutions that span BBB penetration, intracranial orthotopic microenvironment, diffuse infiltration, postoperative relapse, and immune microenvironment evaluation. If you are interested in our services, please don't hesitate to contact us to learn how we can accelerate your GBM/HGG drug development.
Reference
- Singh S, et al. Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal Transduct Target Ther. 2025;10(1):213.
For research use only.
Related Services